Upatinib medical insurance coverage: new indications in 2025

Upadacitinib is a JAK1 selective inhibitor that has been widely used in recent years. Since its approval in Europe and the United States in 2019, its therapeutic indications have gradually expanded to include rheumatoid arthritis, psoriatic arthritis, ankylosing spondylitis, atopic dermatitis, ulcerative colitis and many other immune-related fields. The drug was developed by AbbVie. With its stronger target selectivity and lower side effects, it has gradually become one of the representative drugs in the field of JAK inhibitors. In recent years, with the increasing acceptance of targeted immunomodulatory drugs in China and Asia, upadatinib has gradually been included in the scope of national medical insurance negotiations and has received widespread attention.

Up to now, upadatinib has been included in the reimbursement scope of some indications in China’s medical insurance drug catalog, mainly for indications such as moderate to severe active rheumatoid arthritis. According to predictions, by 2025, the drug is expected to be covered by medical insurance for other indications, marking a further deepening of its policy recognition in the diversification of immunotherapy. This trend not only conforms to the development direction of global precision medicine, but also alleviates the problem of patients being unable to receive long-term treatment due to high drug costs.

Whether upadatinib can be successfully included in new medical insurance indications mainly depends on a number of core factors, including real-world efficacy, safety data accumulation, economic evaluation (such as cost-effectiveness ratio), the degree of recommendation from international guidelines, and its substitution and independence from other treatment options. Taking atopic dermatitis as an example, this indication has the characteristics of high incidence, long course, and heavy treatment burden. Upadatinib has shown excellent results in controlling refractory dermatitis, improving skin itching, and reducing the recurrence rate.

At the same time,the 2025 medical insurance catalog negotiation policy pays more attention to the accessibility of medicines to patients and the long-term expression of clinical value. Therefore, if the therapeutic advantages of upadatinib are further verified in more large-sample studies and real-world databases, it will greatly increase the possibility of being included in new medical insurance indications.

Reference materials:https://www.rinvoq.com/